AVEO Oncology, an LG Chem company
AVEO Oncology (AVEO) is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO’s strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to do the same in other geographies. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA efficacy, safety, and relevant resources, visit our website at FOTIVDAHCP.com.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No